Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 302Carboplatin 230Cisplatin 159Paclitaxel 153Gemcitabine 153Pemetrexed 122Bevacizumab 121Docetaxel 105durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 52Lenalidomide 51venetoclax 47Prednisone 45Irinotecan 42enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Histamine Antagonists × 90 days × Clear all
NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06305754 2026-05-29

MK-2870-009

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
520 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡